Biotechnology

Compendium, compendia, compendial: Clearing up the mystery of these terms

In conversations about the role of quality standards in public health, you might come across the words “compendia” and “compendial.” At USP, terms like “compendial approaches,” “compendial standards,” and “compendial tools” are part of our everyday vocabulary. But their meaning can be a bit of a mystery to people who work outside of the pharmaceutical industry and regulatory bodies.

Share

Previewing Synthetic Therapeutic Peptides Workshop

Peptide Workshop Preview

USP’s popular peptide workshop is back for a third year. Here’s what you can expect.

Share

Our Concerns Regarding Congressional Proposal to Discard Public Quality and Safety Standards for Biologics

Biologics Standards Proposal

For a hundred years, federal law has required that all drugs adhere to public quality standards—part of ensuring safety and protecting the public’s health. Language that would exempt biologics, including biosimilars, from adhering to the same public quality standards as other prescription medicines was recently added to the FDA and NIH Workforce Authorities Modernization Act. Learn about the potential impact this biologics quality exemption may have on competition, product development, and the public's confidence in biologics and biosimilars.

Share